Guggenheim Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Cuts Target Price to $8
A Quick Look at Today's Ratings for Zentalis Pharmaceuticals(ZNTL.US), With a Forecast Between $8 to $20
Zentalis Pharma Analyst Ratings
A Quick Look at Today's Ratings for Zentalis Pharmaceuticals(ZNTL.US), With a Forecast Between $8 to $9
Cautious Hold on Zentalis Pharmaceuticals Amid Strategic Shifts and Safety Concerns
Zentalis Pharmaceuticals: Strong Leadership and Promising Clinical Developments Justify Buy Rating
Stifel Nicolaus Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
Stifel Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $9
Morgan Stanley Downgrades Zentalis Pharmaceuticals(ZNTL.US) to Hold Rating, Cuts Target Price to $8
Maintaining Hold on Zentalis Pharmaceuticals Amidst Positive Regulatory Developments and Upcoming Clinical Milestones
TD Cowen Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating
Zentalis Pharma Analyst Ratings
Oppenheimer Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $20
Zentalis Pharmaceuticals Price Target Announced at $4.00/Share by Wedbush
Wells Fargo Sticks to Their Hold Rating for Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharma Analyst Ratings
TD Cowen Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating
Buy Rating Affirmed for Zentalis Pharmaceuticals Amidst Clinical Progress and Regulatory Optimism
Zentalis Pharma Analyst Ratings
Wells Fargo Downgrades Zentalis Pharmaceuticals to Equal Weight From Overweight, Lowers Price Target to $9 From $29